Nesa Medtech
Founded 2016 · 25 employees on LinkedIn · 2 known investors
Nesa Medtech develops GYIDE, a minimally invasive, uterus-preserving medical device that uses a guidance and planning system to deliver treatment that shrinks uterine fibroids without cutting or suturing. The company targets women's health, offering an alternative to existing surgical and non-surgical treatments for uterine fibroids.
Also known as Nesa Medtech
Investors · 2
Company profile
researched Aug 2026Nesa Medtech is a medical device company focused on women's health, specifically the treatment of uterine fibroids. Its stated mission is to develop minimally invasive surgical solutions using technology while adhering to global quality standards, supported by a multidisciplinary team.
The company's flagship product, GYIDE, is described as a minimally invasive, uterus-preserving technology for treating uterine fibroids. It consists of a guidance and planning system that delivers treatment intended to shrink fibroids and provide symptomatic relief, without cutting or suturing. Claimed characteristics include faster recovery, shorter procedure time and preservation of the uterus.
▸Full profile — market position, technology, go-to-market
Market position
The company frames existing fibroid treatments as either invasive or inaccessible: surgical approaches by gynecologists involve cutting and suturing, longer recovery and operating-theatre use, while non-surgical approaches by interventional radiologists avoid cutting and suturing but entail longer procedure times and expensive infrastructure. Nesa Medtech positions GYIDE as an alternative addressing both sets of drawbacks.
Positioned as a scarless, uterus-preserving procedure with no cutting or suturing, shorter procedure time and faster recovery compared with existing surgical and non-surgical fibroid treatments.
Technology
GYIDE is presented as a precise guidance and planning system that delivers treatment to shrink uterine fibroids, performed without incision or suturing and without removal of the uterus.
Go-to-market
Women affected by uterine fibroids and the clinicians who treat them, including gynecologists and interventional radiologists whose current approaches the company positions GYIDE against.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 1
primary sources listed
- Nesa Medtechnesamedtech.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Nesa Medtech do?
- Nesa Medtech develops GYIDE, a minimally invasive, uterus-preserving technology to treat uterine fibroids.
- Who are Nesa Medtech's investors?
- Nesa Medtech's investors include Malpani Ventures, SucSEED Indovation.